View all cases
UPC APP 4496/2025
EP4183412 Unitary patent · RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME
- Case details
- Status—ActionProcedural applicationCategoryOther procedural
- Parties
- Claimants
- GlaxoSmithKline Biologicals SAOperating co.
Representatives- Oliver Jan Jüngst-Bird & Bird LLP
- Luca Brons-Bird & Bird LLP
- Daniela Kinkeldeysupporting-Bird & Bird LLP
- Anna Schadelsupporting-Bird & Bird LLP
Respondents- Pfizer Europe MA EEIGOperating co.
- Pfizer Manufacturing Belgium NVOperating co.
- Pfizer Pharma GmbHOperating co.
- Pfizer Corporation Austria GmbHOperating co.
- Pfizer S.A.Operating co.
- Pfizer ApSOperating co.
- Pfizer OyOperating co.
- Pfizer SASOperating co.
- Pfizer S.r.l.Operating co.
- Pfizer B.V.Operating co.
- Laboratórios Pfizer, Lda.Operating co.
- Pfizer ABOperating co.
- Pfizer Luxembourg SARLOperating co.
- Pfizer Service Company S.R.L.Operating co.
Representatives- Gareth Williams-Marks & Clerk LLP
- Claudia Milbradt-Clifford Chance Partnerschaft mbB
- Tobias J. Hessel-Clifford Chance Partnerschaft mbB
- Division
- Dusseldorf LD
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- —
- First decided
- Mar 4, 2025
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Dusseldorf LD | Locked |
| Judge Ronny Thomas | Locked |
| Judge Jule Schumacher | Locked |
| Judge Andrea Postiglione | Locked |
At the UPC: GlaxoSmithKline Biologicals SA (20 cases)·Pfizer Group (31 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 8 other proceedings
UPC CFI 687/2024·UPC CFI 476/2024·UPC CFI 468/2024·UPC APP 16306/2025·UPC APP 16366/2025 and 3 more
Start a free trial to see how each one ended.
More cases: Dusseldorf LD·2025
Decisions
- 2025-03-04
Summary: The Düsseldorf Local Division issued a procedural order in the GlaxoSmithKline v Pfizer RSV vaccine case (EP4183412), deciding to bifurcate by referring the counterclaim for revocation to the Milan Central Division while proceeding with the infringement action, and granting a one-month extension for Pfizer's rejoinder.
Show the legal issues (4)
- Bifurcation (Art. 33(3) UPCA)
- Referral of counterclaim for revocation to Central Division
- Extension of time period (R.9.3(a) RoP)
- Procedural efficiency
Documents
- 3AB93CFA84D790E909F6012AC3D28DD6_en.pdf2025-03-04EN